NCT01454479: A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma |
|
|
| Unknown status | 1 | 24 | NA | Lapatinib and ixempra, Lapatinib, Ixempra | Hung-Hsueh Chou, GlaxoSmithKline, Bristol-Myers Squibb | Recurrent Endometrial Cancer | 04/13 | 04/14 | | |
